LimeLight of The week is

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

InMed Pharmaceuticals, Inc. is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Investment Considerations

• Extensive portfolio of assets in dermatology, ocular disease and additional indications and cannabinoid biosynthesis
• Positioned to achieve value-driving, near-term corporate milestones with limited investment
• Led by a management team of experienced professionals capable of building value in biopharmaceuticals

Receive Text Alerts from CannabisNewsWire

Text "Cannabis" to 21000

About CannabisNewsWire (CNW)

CannabisNewsWire (CNW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and writers, CNW introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, CNW's innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. CNW is where news, content and information converge.